Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 28Leukemia 8Recurrence 6Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 2Solid Tumors 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Aortic aneurysm, familial thoracic 4 1

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Myeloid × quizartinib × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡